Wednesday, July 8, 2026

Drug profile · INN

abarelix

abarelix (PLENAXIS) is a gonadotropin-releasing hormone receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — abarelix
US status
approved
Class
Route
INTRAMUSCULAR
Patents
0
Programs
1
Data quality
0.84

Quick answer

abarelix (PLENAXIS) is a gonadotropin-releasing hormone receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN abarelix
Brand PLENAXIS
Mechanism Gonadotropin-releasing hormone receptor antagonist
Target Gonadotropin-releasing hormone receptor
Route INTRAMUSCULAR
Formulation POWDER

Mechanism of action

Gonadotropin-releasing hormone receptor antagonist

Primary target: Gonadotropin-releasing hormone receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. LI Phase 3 · Teva Pharma · Squamous Cell Carcinoma of the Oral Cavity

Related & competitor drugs

  1. cetrorelix acetate Gonadotropin-releasing hormone receptor antagonist
  2. elagolix Gonadotropin-releasing hormone receptor antagonist
  3. ganirelix acetate Gonadotropin-releasing hormone receptor antagonist
  4. leuprolide acetate Gonadotropin-releasing hormone receptor agonist
  5. degarelix acetate Gonadotropin-releasing hormone receptor antagonist
  6. elagolix sodium Gonadotropin-releasing hormone receptor antagonist

Frequently asked questions

What is abarelix?

abarelix (PLENAXIS) is a gonadotropin-releasing hormone receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for abarelix?

PLENAXIS is a marketed brand name for abarelix. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of abarelix?

abarelix has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.